TMPO and neoplasm: TP5, a small 24-amino-acid peptide developed at the National Institutes of Health (NIH), specifically inhibits the tumor-related CDK5/p25 activity while preserving the normal endogenous CDK5/p35 form and its physiological functions [15,16].